<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03542097</url>
  </required_header>
  <id_info>
    <org_study_id>TEMIRI-EW</org_study_id>
    <nct_id>NCT03542097</nct_id>
  </id_info>
  <brief_title>Assessment of MGMT Promoter Methylation in Advanced Ewing Sarcoma Treated With Temozolomide and Irinotecan</brief_title>
  <acronym>MGMTLiberati</acronym>
  <official_title>Assessment of MGMT Promoter Methylation and Clinical Benefit From Temozolomide-based Therapy in Ewing Sarcoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Ortopedico Rizzoli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regione Emilia Romagna - Italy within PRU-Liberati project</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Istituto Ortopedico Rizzoli</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a biological study in patients with advanced Ewing Sarcoma who received, according,
      clinical practice, temozolomide and irinotecan The O6-methylguanine-DNA methyltransferase
      (MGMT) methylation status, will be correlated with the disease clinical data and with the
      disease response
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a biological study in patients with advanced Ewing Sarcoma who received, according,
      clinical practice, temozolomide and irinotecan.

      The MGMT methylation status will be correlated with the disease clinical data and with the
      disease response also in term of metabolic activity (if data will be available) The MGMT
      methylation analysis will be performed extracting from fresh tumor sample, the DNA on the
      basis of the standard protocols.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 15, 2014</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of MGMT promoter methylation</measure>
    <time_frame>at day 1</time_frame>
    <description>Amplification the methylation-specific Polymerase Chain Reaction products will be electrophoresed on a 2% agarose gel and will visualized with UV light</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of the MGMT promoter methylation to the activity of the temozolomide irinotecan combination</measure>
    <time_frame>at month 2, 4, 6, 8, 10 and 12</time_frame>
    <description>Correlation with level of MGMT methylation with tumor response</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">82</enrollment>
  <condition>Ewing Sarcoma Family of Tumors</condition>
  <arm_group>
    <arm_group_label>Temozolomide and Irinotecan treatment</arm_group_label>
    <description>The group include all the patients with histological confirmed diagnosis of Ewing's Sarcoma who received chemotherapic treatment with temozolomide and irinotecan. In this group the MGMT methylation evaluation will be done</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MGMT methylation evaluation</intervention_name>
    <description>The MGMT methylation will be evaluated by extracting DNA from fresh and Formalin Fixed paraffin Embedded (FFPE) tumor samples</description>
    <arm_group_label>Temozolomide and Irinotecan treatment</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Fresh and Formaline Fixed Paraffin Embeded tumor samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with advanced Ewing Sarcoma treated in clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological confirmed diagnosis of Ewing Sarcoma

          2. Chemotherapic treatment with temozolomide and irinotecan

          3. Written informed consent prior to any study related activities

        Exclusion Criteria:

          1. Lack of written informed consent for the study

          2. Any situation that could interfere with the complete data collection of the clinical
             data related to the temozolomide and irinotecan treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emanuela Palmerini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rizzoli Orthopedic Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emanuela Palmerini, MD</last_name>
    <phone>00390513666</phone>
    <phone_ext>199</phone_ext>
    <email>emanuela.palmerini@ior.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fondazione IRCCS - Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <state>Mi</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Istituto di Candiolo - Fondazione del Piemonte per l'Oncologia - IRCCS</name>
      <address>
        <city>Candiolo</city>
        <state>Turin</state>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Orthopedic Rizzoli Institute</name>
      <address>
        <city>Bologna</city>
        <zip>40136</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emanuela Palmerini, MD</last_name>
      <phone>00390516366</phone>
      <phone_ext>199</phone_ext>
      <email>emanuela.palmerini@ior.it</email>
    </contact>
    <investigator>
      <last_name>Emanuela Palmerini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale infantile Regina Margherita</name>
      <address>
        <city>Turin</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robin Jones, MD</last_name>
      <phone>00442078082200</phone>
      <phone_ext>2590</phone_ext>
      <email>robin.jones4@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Robin Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol. 2001 Feb 1;19(3):870-80. Review.</citation>
    <PMID>11157041</PMID>
  </reference>
  <reference>
    <citation>Bacci G, Ferrari S, Longhi A, Donati D, De Paolis M, Forni C, Versari M, Setola E, Briccoli A, Barbieri E. Therapy and survival after recurrence of Ewing's tumors: the Rizzoli experience in 195 patients treated with adjuvant and neoadjuvant chemotherapy from 1979 to 1997. Ann Oncol. 2003 Nov;14(11):1654-9.</citation>
    <PMID>14581274</PMID>
  </reference>
  <reference>
    <citation>Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, Meyers PA. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer. 2009 Dec;53(6):1029-34. doi: 10.1002/pbc.22206.</citation>
    <PMID>19637327</PMID>
  </reference>
  <reference>
    <citation>Donson AM, Addo-Yobo SO, Handler MH, Gore L, Foreman NK. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Pediatr Blood Cancer. 2007 Apr;48(4):403-7.</citation>
    <PMID>16609952</PMID>
  </reference>
  <reference>
    <citation>Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005 Mar 10;352(10):997-1003.</citation>
    <PMID>15758010</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 17, 2018</study_first_submitted>
  <study_first_submitted_qc>May 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2018</study_first_posted>
  <last_update_submitted>May 30, 2018</last_update_submitted>
  <last_update_submitted_qc>May 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ewing Sarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No Plan</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 7, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT03542097/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

